The ESMO Immuno-Oncology 2024 programme is online!
Learning objectives
- Access immersion sessions on the principles of immunobiology and immune therapeutics
- Review highlights on the scientific breakthroughs on novel diagnostics, biomarkers and therapeutic strategies in immuno-oncology
- Understand recent developments on immune modulation, including tumour microenvironment, immunometabolism, epigenetics or microbiome
- Connect and obtain insights on activities of IO research consortia
Accreditation
ESMO-MORA: The ESMO Immuno-Oncology 2024 programme will be submitted for ESMO-MORA category 1 points accreditation. Recertification is necessary for medical oncologists to remain professionally certified by ESMO. It also guarantees that a certified medical oncologist has continued to update her/his knowledge and still possess the necessary skills and standards for the practice of medical oncology. See here for further details.
Disclaimer
ESMO is a scientific and professional, non-political and non-religious organisation. ESMO will not accept responsibility for any comments or remarks made during any of our events by session chairs, invited speakers, presenters, members or any other contributor, formally or informally, which might cause offence or be perceived as being biased.
The experts invited by ESMO as abstract Discussants are selected on an individual basis to provide their own interpretation of the data and are not acting as ESMO spokespersons.
All Speakers and Discussants are required to declare their interests, if any, and include a Declaration of Interest (DOI) slide at the start of their presentation(s).
The ESMO recommendations on the clinical utility of new drugs are only presented in the ESMO Clinical Practice Guidelines and such recommendations represent the only official position of ESMO.